Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26;71(34):1085-1091.
doi: 10.15585/mmwr.mm7134a3.

Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022

Collaborators, Affiliations

Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022

Fiona P Havers et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).

Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Andrea George reports grant support from the Council of State and Territorial Epidemiologists (CSTE). Nancy E. Moran reports grant support from CSTE for the population-based Influenza Hospitalization Surveillance Project and COVID-NET activities. Libby Reeg reports institutional support from CSTE. Andy Weigel reports grant support from CSTE for influenza surveillance activities. Evan J. Anderson reports grants for clinical trials from Pfizer, Merck, PaVax, Micron, Sanofi-Pasteur, Janssen, MedImmune, and GlaxoSmithKline; consulting fees from Sanofi-Pasteur, Pfizer, Medscape, Janssen, GlaxoSmithKline, and Moderna; membership on a Kentucky Bioprocessing, Inc., data safety monitoring board and a Sanofi-Pasteur data safety monitoring board, and the endpoint adjudication committee for WCG and ACI Clinical and institutional funding from the National Institutes of Health to conduct clinical trials of COVID-19 vaccines. No other potential conflicts of interest were disclosed.

Figures

FIGURE 1
FIGURE 1
Weekly COVID-19-associated hospitalization rates among adults aged ≥18 years, by age group and period of COVID-19 variant predominance — COVID-19–Associated Hospitalization Surveillance Network, 14 states, weeks ending June 26, 2021–May 28, 2022 * SARS-CoV-2 variant predominance defined by period when variant accounted for >50% of sequenced isolates. † Data are collected in selected counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. A list of these counties is available at https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Iowa did not provide immunization data but is included in the overall population-based hospitalization rates. Additional information on surveillance methods is available at https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html. § Maryland did not contribute data after December 4, 2021, but did contribute data for previous weeks.
FIGURE 2
FIGURE 2
COVID-19–associated hospitalization rate ratios among adults aged ≥18 years, by age group and period of COVID-19 variant predominance — COVID-19–Associated Hospitalization Surveillance Network, 14 states, July 2021–May 2022 * Adults aged 18–49 years are the referent group; the rate ratio for this group is 1.0 for all periods. Data are collected in selected counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. A list of these counties is available at https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Iowa did not provide immunization data but is included in the overall population-based hospitalization rates. Additional information on surveillance methods is available at https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html. § Maryland did not contribute data after December 4, 2021, but did contribute data for previous weeks.

Similar articles

Cited by

References

    1. Massetti GM, Jackson BR, Brooks JT, et al. Summary of guidance for minimizing the impact of COVID-19 on individual persons, communities, and health care systems—United States, August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1057–64. 10.15585/mmwr.mm7133e1 - DOI - PMC - PubMed
    1. Havers FP, Pham H, Taylor CA, et al. COVID19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years—COVID-NET, 13 states, January 1, 2021–April 30, 2022. JAMA Intern Med. In press 2022. - PMC - PubMed
    1. Delahoy MJ, Whitaker M, O’Halloran A, et al. ; COVID-NET Surveillance Team. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19—COVID-NET, 13 States, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1347–54. 10.15585/mmwr.mm6938e1 - DOI - PMC - PubMed
    1. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–64. 10.15585/mmwr.mm6915e3 - DOI - PMC - PubMed
    1. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated—VISION Network, 10 states, December 2021–June 2022. MMWR Morb Mortal Wkly Rep 2022;71:931–9. 10.15585/mmwr.mm7129e1 - DOI - PMC - PubMed

Substances